Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies

Circulation Research

Volumn 120, Issue 8, 2017, Pages 1326-1340

  Rigato, Mauro ^a   Monami, Matteo ^b   Fadini, Gian Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

angiogenesis; diabetes mellitus; epidemiology; mortality; regeneration; stem cells

Indexed keywords

AMPUTATION; ANKLE BRACHIAL INDEX; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW DERIVED MONONUCLEAR CELL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; MESENCHYMAL STEM CELL; META ANALYSIS; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRANSCUTANEOUS OXYGEN MONITORING; WOUND HEALING; ADVERSE EFFECTS; AGED; AUTOTRANSPLANTATION; CHI SQUARE DISTRIBUTION; CONVALESCENCE; DISEASE FREE SURVIVAL; FEMALE; ISCHEMIA; LIMB SALVAGE; MALE; MIDDLE AGED; MORTALITY; ODDS RATIO; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; REGENERATION; RISK FACTOR; STEM CELL TRANSPLANTATION; TIME FACTOR; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; AMPUTATION; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ISCHEMIA; LIMB SALVAGE; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; REGENERATION; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VASCULAR PATENCY; WOUND HEALING;

EID: 85010866436     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.309045     Document Type: Review

References (67)

1. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME, 2016 aha/acc guideline on the management of patients with lower extremity peripheral artery disease: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 2016
2. Nehler MR, Duval S, Diao L, Annex BH, Hiatt WR, Rogers K, Zakharyan A, Hirsch AT, Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg 2014 60 686 695.e2. doi: 10.1016/j.jvs.2014.03.290.
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007 45 suppl S S5 67. doi: 10.1016/j.jvs.2006.12.037.
4. Vartanian SM, Conte MS, Surgical intervention for peripheral arterial disease. Circ Res 2015 116 1614 1628. doi: 10.1161/CIRCRESAHA.116.303504.
5. Thukkani AK, Kinlay S, Endovascular intervention for peripheral artery disease. Circ Res 2015 116 1599 1613. doi: 10.1161/CIRCRESAHA.116.303503.
6. Egorova NN, Guillerme S, Gelijns A, Morrissey N, Dayal R, McKinsey JF, Nowygrod R, An analysis of the outcomes of a decade of experience with lower extremity revascularization including limb salvage, lengths of stay, and safety. J Vasc Surg 2010 51 878 885, 885.e1. doi: 10.1016/j.jvs.2009.10.102.
7. Reinecke H, Unrath M, Freisinger E, Bunzemeier H, Meyborg M, Lüders F, Gebauer K, Roeder N, Berger K, Malyar NM, Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J 2015 36 932 938. doi: 10.1093/eurheartj/ehv006.
8. Siegel RL, Miller KD, Jemal A, Cancer statistics, 2015. CA Cancer J Clin 2015 65 5 29. doi: 10.3322/caac.21254.
9. Lambert MA, Belch JJ, Medical management of critical limb ischaemia: where do we stand today? J Intern Med 2013 274 295 307. doi: 10.1111/joim.12102.
10. Cooke JP, Chen Z, A compendium on peripheral arterial disease. Circ Res 2015 116 1505 1508. doi: 10.1161/CIRCRESAHA.115.306403.
11. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM, Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999 85 221 228
12. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM, Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997 275 964 967
13. Raval Z, Losordo DW, Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ Res 2013 112 1288 1302. doi: 10.1161/CIRCRESAHA.113.300565.
14. Peeters Weem SM, Teraa M, de Borst GJ, Verhaar MC, Moll FL, Bone Marrow derived Cell Therapy in Critical Limb Ischemia: A Meta-analysis of Randomized Placebo Controlled Trials. Eur J Vasc Endovasc Surg 2015 50 775 783. doi: 10.1016/j.ejvs.2015.08.018.
15. Liew A, Bhattacharya V, Shaw J, Stansby G, Cell Therapy for Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials. Angiology 2016 67 444 455. doi: 10.1177/0003319715595172.
16. Wang ZX, Li D, Cao JX, Liu YS, Wang M, Zhang XY, Li JL, Wang HB, Liu JL, Xu BL, Efficacy of autologous bone marrow mononuclear cell therapy in patients with peripheral arterial disease. J Atheroscler Thromb 2014 21 1183 1196
17. Teraa M, Sprengers RW, van der Graaf Y, Peters CE, Moll FL, Verhaar MC, Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 2013 258 922 929. doi: 10.1097/SLA.0b013e3182854cf1.
18. Benoit E, O'Donnell TF, Patel AN, Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review. Cell Transplant 2013 22 545 562. doi: 10.3727/096368912X636777.
19. Wen Y, Meng L, Gao Q, Autologous bone marrow cell therapy for patients with peripheral arterial disease: a meta-analysis of randomized controlled trials. Expert Opin Biol Ther 2011 11 1581 1589. doi: 10.1517/14712598.2011.626401.
20. Fadini GP, Agostini C, Avogaro A, Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010 209 10 17. doi: 10.1016/j.atherosclerosis.2009.08.033.
21. Gyöngyösi M, Wojakowski W, Navarese EP, Moye LÀ ACCRUE Investigators Meta-analyses of human cell-based cardiac regeneration therapies: controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ Res 2016 118 1254 1263. doi: 10.1161/CIRCRESAHA.115.307347.
22. Nowbar AN, Mielewczik M, Karavassilis M, Dehbi HM, Shun-Shin MJ, Jones S, Howard JP, Cole GD, Francis DP, DAMASCENE writing group Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ 2014 348 g2688
23. Moyé L, DAMASCENE and meta-ecological research: a bridge too far. Circ Res 2014 115 484 487. doi: 10.1161/CIRCRESAHA.114.304767.
24. Martin-Rendon E, Meta-analyses of human cell-based cardiac regeneration therapies: what can systematic reviews tell us about cell therapies for ischemic heart disease? Circ Res 2016 118 1264 1272. doi: 10.1161/CIRCRESAHA.115.307540.
25. Gyöngyösi M, Wojakowski W, Lemarchand P, ACCRUE Investigators Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 2015 116 1346 1360. doi: 10.1161/CIRCRESAHA.116.304346.
26. Fisher SA, Doree C, Mathur A, Martin-Rendon E, Meta-analysis of cell therapy trials for patients with heart failure. Circ Res 2015 116 1361 1377. doi: 10.1161/CIRCRESAHA.116.304386.
27. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009 6 e1000100. doi: 10.1371/journal.pmed.1000100.
28. Higgins J, Green S, The Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated march 2011) 2011 The Cochrane Collaboration
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG, Measuring inconsistency in meta-analyses. BMJ 2003 327 557 560. doi: 10.1136/bmj.327.7414.557.
30. Begg CB, Mazumdar M, Operating characteristics of a rank correlation test for publication bias. Biometrics 1994 50 1088 1101
31. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group; Cochrane Statistical Methods Group The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011 343 d5928
32. Powell RJ, Marston WA, Berceli SA, Guzman R, Henry TD, Longcore AT, Stern TP, Watling S, Bartel RL, Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther 2012 20 1280 1286. doi: 10.1038/mt.2012.52.
33. Szabó GV, Kövesd Z, Cserepes J, Daróczy J, Belkin M, Acsády G, Peripheral blood-derived autologous stem cell therapy for the treatment of patients with late-stage peripheral artery disease-results of the short-and long-term follow-up. Cytotherapy 2013 15 1245 1252. doi: 10.1016/j.jcyt.2013.05.017.
34. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S, Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011 92 26 36. doi: 10.1016/j.diabres.2010.12.010.
35. Barc P, Skora J, Pupka A, Turkiewicz D, Dorobisz A, J. G, Tomasiewicz B, Szyber P, Bone-marrow cells in therapy of critical limb ischaemia of lower extremities-own experience. Acta Angiol 2006 12 155 166
36. Sterne JA, Sutton AJ, Ioannidis JP, Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011 343 d4002
37. Wetterslev J, Thorlund K, Brok J, Gluud C, Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008 61 64 75. doi: 10.1016/j.jclinepi.2007.03.013.
38. Klepanec A, Mistrik M, Altaner C, Valachovicova M, Olejarova I, Slysko R, Balazs T, Urlandova T, Hladikova D, Liska B, Tomka J, Vulev I, Madaric J, No difference in intra-arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplant 2012 21 1909 1918. doi: 10.3727/096368912X636948.
39. Van Tongeren RB, Hamming JF, Fibbe WE, Van Weel V, Frerichs SJ, Stiggelbout AM, Van Bockel JH, Lindeman JH, Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino) 2008 49 51 58
40. Gremmels H, Teraa M, Quax PH, den Ouden K, Fledderus JO, Verhaar MC, Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls. Mol Ther 2014 22 1960 1970. doi: 10.1038/mt.2014.161.
41. Huang PP, Yang XF, Li SZ, Wen JC, Zhang Y, Han ZC, Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007 98 1335 1342
42. Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, Ito M, Saito Y, Uemura S, Suzuki H, Fukumoto S, Yamamoto Y, Onodera R, Teramukai S, Fukushima M, Matsubara H, TACT Follow-up Study Investigators Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008 156 1010 1018. doi: 10.1016/j.ahj.2008.06.025.
43. Horie T, Onodera R, Akamastu M, Ichikawa Y, Hoshino J, Kaneko E, Iwashita C, Ishida A, Tsukamoto T, Teramukai S, Fukushima M, Kawamura A, Japan Study Group of Peripheral Vascular Regeneration Cell Therapy (JPRCT) Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells. Atherosclerosis 2010 208 461 466. doi: 10.1016/j.atherosclerosis.2009.07.050.
44. Onodera R, Teramukai S, Tanaka S, Kojima S, Horie T, Matoba S, Murohara T, Matsubara H, Fukushima M, BMMNC Follow-Up Study Investigators; M-PBMNC Follow-Up Study Investigators Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis. Bone Marrow Transplant 2011 46 278 284. doi: 10.1038/bmt.2010.110.
45. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T, Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002 360 427 435. doi: 10.1016/S0140-6736(02)09670-8.
46. Losordo DW, Kibbe MR, Mendelsohn F, Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012 5 821 830. doi: 10.1161/CIRCINTERVENTIONS.112.968321.
47. Cobellis G, Silvestroni A, Lillo S, Sica G, Botti C, Maione C, Schiavone V, Rocco S, Brando G, Sica V, Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant 2008 42 667 672. doi: 10.1038/bmt.2008.228.
48. N apoli C, Farzati B, Sica V, Iannuzzi E, Coppola G, Silvestroni A, Balestrieri ML, Florio A, Matarazzo A, Beneficial effects of autologous bone marrow cell infusion and antioxidants/L-arginine in patients with chronic critical limb ischemia. Eur J Cardiovasc Prev Rehabil 2008 15 709 718. doi: 10.1097/HJR.0b013e3283193a0f.
49. Molavi B, Zafarghandi MR, Aminizadeh E, Hosseini SE, Mirzayi H, Arab L, Baharvand H, Aghdami N, Safety and efficacy of repeated bone marrow mononuclear cell therapy in patients with critical limb iIschemia in a pilot randomized controlled trial. Arch Iran Med 2016 19 388 396. doi: 0161906/AIM.004.
50. Giles KA, Rzucidlo EM, Goodney PP, Walsh DB, Powell RJ, Bone marrow aspirate injection for treatment of critical limb ischemia with comparison to patients undergoing high-risk bypass grafts. J Vasc Surg 2015 61 134 137. doi: 10.1016/j.jvs.2014.06.089.
51. Smith GD, Egger M, Who benefits from medical interventions? BMJ 1994 308 72 74
52. Murphy MP, Ross C, Kibbe MR, Kelso RL, Sharafuddin MJ, Tzeng E, Laird JR, Mobile Working Group Administration of autologous bone marrow cells for limb salvage in patients with critical limb ischemia: Results of the multicenter phase III mobile trial. AHA 2016 Late Breaking Clinical Trials. Accessed at http://www.abstractsonline.com/pp8/#!/4096/presentation/58438
53. Perin EC, Murphy M, Cooke JP, Cardiovascular Cell Therapy Research Network Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells. Am Heart J 2014 168 667 673. doi: 10.1016/j.ahj.2014.07.021.
54. Perin EC, Murphy M, March K, Administration of ALDH bright cells to patients with intermittent claudication: The NHLBI CCTRN Pace Trial. AHA 2016 Late Breaking Clinical Trials. Accessed at http://www.abstractsonline.com/pp8/#!/4096/presentation/58439
55. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ, Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993 342 1032 1036
56. Cooke JP, Losordo DW, Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res 2015 116 1561 1578
57. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE Working Group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008 336 924 926. doi: 10.1136/bmj.39489.470347.AD.
58. Albiero M, Menegazzo L, Boscaro E, Agostini C, Avogaro A, Fadini GP, Defective recruitment, survival and proliferation of bone marrow-derived progenitor cells at sites of delayed diabetic wound healing in mice. Diabetologia 2011 54 945 953. doi: 10.1007/s00125-010-2007-2.
59. Fadini GP, Sartore S, Schiavon M, Albiero M, Baesso I, Cabrelle A, Agostini C, Avogaro A, Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 2006 49 3075 3084. doi: 10.1007/s00125-006-0401-6.
60. Fadini GP, Ciciliot S, Albiero M, Concise Review: Perspectives and Clinical Implications of Bone Marrow and Circulating Stem Cell Defects in Diabetes. Stem Cells 2017 35 106 116. doi: 10.1002/stem.2445.
61. Sun L, Wu L, Qiao Z, Yu J, Li L, Li S, Liu Q, Hu Y, Xu N, Huang P, Analysis of possible factors relating to prognosis in autologous peripheral blood mononuclear cell transplantation for critical limb ischemia. Cytotherapy 2014 16 1110 1116. doi: 10.1016/j.jcyt.2014.03.007.
62. Benoit E, O'Donnell TF Jr, Iafrati MD, Asher E, Bandyk DF, Hallett JW, Lumsden AB, Pearl GJ, Roddy SP, Vijayaraghavan K, Patel AN, The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med 2011 9 165. doi: 10.1186/1479-5876-9-165.
63. Tokita Y, Tang XL, Li Q, Wysoczynski M, Hong KU, Nakamura S, Wu WJ, Xie W, Li D, Hunt G, Ou Q, Stowers H, Bolli R, Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy. Circ Res 2016 119 635 651. doi: 10.1161/CIRCRESAHA.116.308937.
64. Hernández P, Cortina L, Artaza H, Pol N, Lam RM, Dorticós E, Macías C, Hernández C, del Valle L, Blanco A, Martínez A, Díaz F, Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: a comparison of using blood cell separator and Ficoll density gradient centrifugation. Atherosclerosis 2007 194 e52 e56. doi: 10.1016/j.atherosclerosis.2006.08.025.
65. Procházka V, Gumulec J, Jalůvka F, Salounová D, Jonszta T, Czerný D, Krajča J, Urbanec R, Klement P, Martinek J, Klement GL, Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010 19 1413 1424. doi: 10.3727/096368910X514170.
66. Maione C, Botti C, Coppola CA, Silvestroni C, Lillo S, Schiavone V, Sica G, Sica V, Kumar V, Cobellis G, Effect of autologous transplantation of bone marrow cells concentrated with the MarrowXpress system in patients with critical limb ischemia. Transplant Proc 2013 45 402 406. doi: 10.1016/j.transproceed.2012.10.031.
67. Celis P, Ferry N, Hystad M, Schüßler-Lenz M, Doevendans PA, Flory E, Beuneu C, Reischl I, Salmikangas P, Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market-Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014. Transfus Med Hemother 2015 42 194 199. doi: 10.1159/000382107.